EUCTR2008-007647-14-FI进行中（未招募）不适用
The effect of fluvoxamine and ciprofloxacin on the pharmacokinetics and pharmacodynamics of nabumetone: A three-phase double-blind placebo-controlled cross-over study.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The study will be carried out with 12 healthy volunteers aged 18 to 40 years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A previous history of intolerance to the study drugs or to related compounds and additives.
- •2. Concomitant drug therapy known to cause enzyme induction or inhibition for at least 30 days prior to the study.
- •3. Concomitant drug therapy of any kind for at least 14 days prior to the study.
- •4. Subjects younger than 18 years and subjects over 40 years.
- •5. Existing or history of asthma, seizures, hematological, endocrine, significant metabolic, significant cardiovascular, psychiatric or gastrointestinal disease, including gut motility disorders or any other significant disease or drug allergy.
- •6. Previous or present alcoholism, drug abuse, psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.
- •7. Pregnancy or nursing.
- •8. Use of hormonal contraception for at least 30 days prior to the study.
- •9. Donation of blood for 4 weeks prior to and during the study.
- •10. Special diet or life style conditions which would compromise the conditions of the study or interpretation of the results.
- •11. Participation in any other studies involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study.
- •12. Smoking for 30 days before the start of the study and during the whole study period.
研究者
相似试验
已完成
4 期
Examining whether any interactions occur between the antibiotic Ciprofloxacin and the antimalarial treatment Chloroquine/ProguanilPharmacokineticsISRCTN20647977Defence Science and Technology Laboratory (Dstl)16
进行中（未招募）
1 期
Pharmacokinetic Interactions between Ciprofloxacin and Chloroquine / Proguanil ProphylaxisChloroquine/proguanil is used for malaria chemoprophylaxis in areas where chloroquine-resistant Plasmodium falciparum malaria is prevalent, except in regions of Africa where chloroquine/proguanil is no longer effective. Ciprofloxacin is a fluoroquinolone antibiotic used to treat a wide variety of infections, such as traveller`s diarrhoea. Only healthy subjects will be treated in this study.EUCTR2005-004905-27-GBDstl16
已完成
3 期
The effects of ciprofloxacin on the treatment of bacterial otitis mediaIRCT20130427013136N7Babol University of Medical Sciences80
已完成
3 期
Fluvoxamine in Long COVIDong or Post COVID syndrome.Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis.U09.9IRCT20220526054990N1Artesh University of Medical Sciences96
已完成
3 期
Comparison of the therapeutic effect of ciprofloxacin and Combination of ciprofloxacin and propolis on women with cystitisIRCT20180721040552N1Ghoum University of Medical Sciences120